In the intricate world of quantum physics, where particles interact in ways that seem to defy the standard rules of space and ...

Aurobindo Pharma's Bone Treatment Drug Shows Promise in Tests Aurobindo Pharma's subsidiary, CuraTeQ Biologics, has announced successful trial results for its new bone treatment medicine. The drug, ...

“It is no use asking for the impossible, such as, say, the exact wiring diagram for a cubic millimeter of brain tissue and the way all its neurons are firing,” Crick wrote in Scientific America ...

Get Instant Summarized Text (Gist) A comprehensive wiring diagram and functional map of a mouse brain's visual cortex, the largest to date, has been created from a cubic millimeter of tissue. This ...

With his extreme new round of tariffs in effect as of Wednesday morning, President Trump’s trade war is at full throttle. Stock markets around the world keep plummeting, and chaos and ...

As the Alaskan who leads the board of the Alaska Gasline Development Corporation (AGDC), I write to provide a frank update about the Alaska LNG Project, which has been in the news a lot lately ...

Applications for the next phase are set to open soon. Phase 5 will focus on candidates aged between 18 and 34 - those turning 35 before the end of March 2026. The new phase is expected to create at ...

Racing toward a $1.6 billion market, the biotech stopped work on RLYB212 in a rare maternal immune disorder in response to phase 2 data. RLYB212, an anti-HPA-1a antibody, was in phase 2 ...

Stifel analysts said that Lexeo’s data showing reduced size and thickness of the heart’s left ventricle are “supportive of a drug effect” for the company’s gene therapy in Friedreich’s ataxia ...

The fifth phase saw earthquakes striking the Bayan Har block on the eastern Tibetan Plateau between 2001 and 2015. The sixth, and current, active phase was centred on the periphery of the Bayan ...

MDX Research Center for Element Strategy, Institute of Integrated Research, Institute of Science Tokyo, 4259 Nagatsuta, Midori, Yokohama 226-8501, Japan MDX Research Center for Element Strategy, ...

The FDA cleared the investigational new drug application for ALX2004, with phase 1 trials expected to begin in mid-2025 for EGFR+ solid tumors. The FDA has cleared the investigational new drug (IND) ...